Kedrion S.p.A.

Kedrion S.p.A.

Paolo Marcucci represents the third generation of the Marcucci family to lead the firm, which began as a small pharmaceutical business in Tuscany. The family's wealth originates from the specialty pharmaceutical sector, specifically plasma-derived therapies. Kedrion invests heavily in research and development, manufacturing infrastructure, and strategic acquisitions. Its asset-class mix includes equity in the core operating business, internal R&D programs, and selective debt financing. The firm owns or operates 11 plasma fractionation facilities across Italy, the United States, Germany, and Hungary. Confirmed acquisitions include the purchase of the plasma fractionation business from BPL in Hungary in 2021, expanding its European capacity. Approximately 4,000 professionals work across the Kedrion group globally. A major recent milestone was the 2023 opening of a new plasma fractionation plant in Georgia, United States (per public record), reinforcing the firm's shift toward U.S. manufacturing. The family also operates the Marcucci Foundation, a philanthropic entity focused on health and education. Kedrion differs from many family offices because its capital is not separated from its operating business — the firm's wealth and its industrial operations are the same entity. This structure funds internal R&D and acquisitions more like a family-held industrial conglomerate than a traditional investment office.